Storia in 2 fonti

SK Bioscience wins W300b policy funding for pneumococcal vaccine

SK Bioscience plans to expedite the late-stage clinical trial of its pneumococcus vaccine by leveraging a 300 billion won ($200 million) government fund. The va

Raccontata da

koreaherald.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

koreaherald.comStai leggendo4 g fa

SK Bioscience wins W300b policy funding for pneumococcal vaccine

SK Bioscience plans to expedite the late-stage clinical trial of its pneumococcus vaccine by leveraging a 300 billion won ($200 million) government fund. The va

originale

morningstar.com4 g fa

SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund

SK bioscience secured KRW 300 billion (~USD 230M) in government-backed financing through Korea's Growth Fund to advance GBP410, a 21-valent pneumococcal conjugate vaccine co-developed with Sanofi, currently in global Phase 3 trials. For biotech and pharma stack decision-makers, this signals Korea's pivot from manufacturing subsidies to funding late-stage global clinical programs, reinforcing Sanofi's partnership model as a capital-efficient path to market for novel vaccine candidates.

Leggi questa versione → originale

Timeline cronologica

venerdì 29 maggio 2026·koreaherald.com
SK Bioscience wins W300b policy funding for pneumococcal vaccine
SK Bioscience plans to expedite the late-stage clinical trial of its pneumococcus vaccine by leveraging a 300 billion won ($200 million) government fund. The va
venerdì 29 maggio 2026·morningstar.com
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund